The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 27, 2018

Filed:

Apr. 10, 2017
Applicants:

University of Maryland, Baltimore, Baltimore, MD (US);

Gliknik Inc., Baltimore, MD (US);

Inventors:

Scott E. Strome, Baltimore, MD (US);

Dan H. Schulze, Baltimore, MD (US);

David S. Block, Baltimore, MD (US);

Henrik Olsen, Baltimore, MD (US);

Assignees:

Gliknik Inc., Baltimore, MD (US);

University of Maryland, Baltimore, Baltimore, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07K 16/00 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); C07K 16/06 (2006.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
C07K 16/00 (2013.01); C07K 16/065 (2013.01); C07K 16/18 (2013.01); C07K 16/28 (2013.01); C07K 16/283 (2013.01); C07K 16/2863 (2013.01); C07K 16/32 (2013.01); G01N 33/5047 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/57 (2013.01); C07K 2317/35 (2013.01); C07K 2317/41 (2013.01); C07K 2317/50 (2013.01); C07K 2317/52 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/528 (2013.01); C07K 2317/53 (2013.01); C07K 2317/55 (2013.01); C07K 2317/71 (2013.01); C07K 2317/72 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2318/00 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01); G01N 2500/10 (2013.01);
Abstract

IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.


Find Patent Forward Citations

Loading…